secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2022-03-09T23:59:59+00:00
Accession:  0001213900-22-011205
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics reports Q4 net loss of $10.2M; cash $130.7M funds operations into mid-2024
--------------------------------------------------------------------------------

- Net loss for Q4 2021 was $10.2M ($0.91 loss per share); full year net loss $47.3M ($4.21 loss per share).
- Cash and marketable securities $130.7M as of Dec 31, 2021; expected to fund operations into mid-2024.
- R&D expenses rose to $4.1M in Q4 (vs $3.7M prior year) and $21.1M for full year (vs $12.0M).
- Phase 1 trial of TARA-002 in non-muscle invasive bladder cancer (NMIBC) has commenced after FDA IND clearance.
- Jathin Bandari, M.D., appointed as Chief Medical Officer in January 2022; previously Interim CMO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390022011205/0001213900-22-011205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390022011205/ea156484-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-011205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer